Amgen applies to broaden use of Blincyto
Biotech company Amgen submitted an application to the U.S. Food and Drug Administration for Blincyto, a drug used in the treatment of lymphoblastic leukemia, to broaden its uses and treatments. Read More »
Biotech company Amgen submitted an application to the U.S. Food and Drug Administration for Blincyto, a drug used in the treatment of lymphoblastic leukemia, to broaden its uses and treatments. Read More »
The U.S. Food and Drug Administration approved Amgen's Parsabiv for the treating of secondary hyperparathyroidism in adults with chronic kidney failure and is administered at dialysis locations throughout the country. Read More »
Charles Holley Jr. has joined the Amgen Board of Directors as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee. Read More »
Biopharmaceutical company Amgen won a major victory in case involving the infringement of two patents held by the company. Read More »
A $1.15 per share dividend was recently declared by Amgen's Board of Directors for the first quarter of next year. Read More »
Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »
Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma. Read More »
Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »
The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »
Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »
Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »
Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »
The U.S. Food and Drug Administration, under a Special Protocol Assessment, has agreed to Athersys' design and analysis of a Multistem Phase 3 study. Read More »
The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »
Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »
Meridian Bioscience Inc. has officially launched its Analyte Specific Reagent (ASR) line of products. Read More »
ProclaRx recently appointed Doug Martin as its new COO, assigning him strategic planning, compliance and coordination of R&D duties. Read More »
Phase III study shows up to 40 percent reduction in seizures in study participants. Read More »